ARCT-032 CF Breakthrough: mRNA Therapy Hope
ARCT-032: A Novel Inhaled mRNA Therapy for Cystic Fibrosis Cystic fibrosis (CF), a genetic disorder causing debilitating lung and digestive issues, affects thousands. Current treatments, primarily CFTR modulators, offer significant benefits, but many CF patients remain ineligible or unresponsive to these therapies. A new hope emerges with ARCT-032, an inhaled messenger RNA (mRNA) therapy currently undergoing clinical trials. Early-stage results suggest a potential breakthrough, particularly for those with CFTR mutations currently considered untreatable....